Using multi-omics to predict treatment outcomes for advanced nasopharyngeal cancer
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for Recurrent and/or Metastatic Nasopharyngeal Carcinoma
This study is testing if new biological methods can help predict how well a combination of chemotherapy and immunotherapy will work for people with advanced nasopharyngeal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06197776 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit 50 patients with recurrent or metastatic nasopharyngeal carcinoma to explore how multi-omics techniques can predict the effectiveness of a treatment regimen that combines chemoradiotherapy with immunotherapy. The study will analyze various biological data to identify potential biomarkers that correlate with treatment response. By understanding these predictive values, the research seeks to enhance personalized treatment strategies for patients suffering from this aggressive cancer.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 70 with recurrent or metastatic nasopharyngeal carcinoma and an ECOG performance status of 0 to 1.
Not a fit: Patients with other malignant tumors, severe complications, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and tailored treatment options for patients with recurrent and metastatic nasopharyngeal carcinoma.
How similar studies have performed: While the use of multi-omics in cancer treatment prediction is an emerging field, similar studies have shown promise in other cancer types, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recurrent or metastatic nasopharyngeal carcinoma patients * All genders，range from 18～70 years old * ECOG score 0 \~ 1 * Inform consent form Exclusion Criteria: * Have or are suffering from other malignant tumors; * Participating in other clinical trials; * Drug or alcohol addition; * Do not have full capacity for civil acts; * Mental disorder; * Pregnancy or lactation; * Severe complication, eg, uncontrolled hypertension.
Where this trial is running
Guangzhou, Guangdong
- Cancer Center, Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Chong Zhao, M.D — Sun Yat-Sen University Cancer Center
- Study coordinator: Jingjing Miao, M.D
- Email: miaojingjing90@163.com
- Phone: 86-13631355201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.